Detalhe da pesquisa
1.
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Lancet Oncol
; 25(5): e205-e216, 2024 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38697166
2.
Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose.
Eur J Neurol
; 31(3): e16164, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38015467
3.
Liver Graft-Versus-Host Disease is associated with poor survival among allogeneic hematopoietic stem cell transplant recipients.
Am J Hematol
; 94(10): 1072-1080, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31292984
4.
Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study.
Clin Lymphoma Myeloma Leuk
; 24(1): 55-63, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37838502
5.
The role of biomarkers in personalized immunotherapy.
Biomark Res
; 10(1): 32, 2022 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35585623
6.
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting.
J Hematol Oncol
; 14(1): 66, 2021 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33879198
7.
Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.
Leuk Lymphoma
; 61(3): 691-698, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31739729
8.
A comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping.
Blood Cancer J
; 14(1): 78, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38702349
9.
Therapy Induced Genome Chaos: A Novel Mechanism of Rapid Cancer Drug Resistance.
Front Cell Dev Biol
; 9: 676344, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34195196